Learning Objectives:

1.    Review The Mechanistic and Therapeutic effects Of  Mineralo- Corticoid   Antagonists In Diabetic Chronic Kidney Disease
2.    Modulate Hyperaldosteronism In the Heart Patient With chronic Kidney Disease
3.    Improve Cardiovascular outcomes  in Diabetic Patients With CKD  And Type 2 Diabetes; (FIDELIO-DKD Randomized Trial)

 

Faculty Disclosure:

George Bakris, MD, Presenter, works as a Consultant/Principal Investigator/Steering Committee of International Trials with Merck, Bayer, KBP Biosciences, Ionis, Alnylam, Astra Zeneca, Quantum Genomics, Horizon, Novo Nordisk related to Kidney Disease/Hypertension/Diabetes.

Faculty does not plan on discussing unlabeled/investigational uses of a commercial product.

Session date: 
02/16/2022 - 12:00pm to 1:00pm EST
Location: 
Boston University Medical Center
Boston, MA
United States
See map: Google Maps
Add to calendar: 
  • 1.00 AMA PRA Category 1 Credit™

    Boston University Chobanian & Avedisian School of Medicine designates this Live activity for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • 1.00 Participation
Please login or register to take this course.